The study was undertaken to evaluate the impact of type II diabetes on patients with hepatocellular carcinoma HCC.
NONALCOHOLIC STEATOHEPATITIS: THE MAINSTAY OF CLINICAL HEPATOLOGY
Material and methods. This is an observational study conducted in the Department of Oncology, Clinical Emergency County Hospital of Constanţa, for a period of four years, from to A total of patients with HCC were analyzed.
The patients were divided in two groups, with and without type II diabetes. In this study, there were included patients with hepatocellular carcinoma. Among all patients with HCC, 94 Of the patients with hepatocellular carcinoma, type II diabetes was found in 37 patients There is no difference between groups in hepatocellular cancer metabolic syndrome to gender. The average age in the group of HCC was 70 years, compared to the group of diabetic patients in which the mean age was of Hepatocellular carcinoma is a common cancer, with increased incidence in our region, hepatitis C and B being shown to be the most frequent causative agent.
Type 2 diabetes was present in The average age at diagnosis of HCC within the group of diabetic patients was significantly lower.
Mean survival was higher in non-diabetic patients and one-year mortality was significant higher in diabetic patients, concluding that diabetes may affect the long-term survival and can worsen the prognosis in these patients.
Studiul a fost făcut pentru a enterobius vermicularis drug of choice impactul diabetului de tip II la pacienții diagnosticați cu carcinom hepatocelular HCC. Materiale și metode.
Está en la página 1de 17 Buscar dentro del documento The Sixth National Symposium of Bariatric and Metabolic Surgery December 6th,Bucharest Carcinomul hepatocelular dezvoltat pe ficatul gras nonalcoolic. Evaluarea riscului la pacienii cu obezitate i sindrom metabolic Hepatocellular Carcinoma in Nonalcoholic Liver Disease. Dnil, D.
Acesta este un studiu observațional desfățurat în Departamentul de Oncologie a Spitalului Județean de Urgență Constanța, cu o durată de patru ani, din până în Au fost analizați în studiu de pacienți cu HCC.
Pacienții au fost împărțiți în două grupuri, cu și fără diabet de tip II. Nu este nici o diferență între grupe în relație cu sexul pacienților.
NAFLD encompasses two distinct conditions with distinct histologic features and prognosis: 1 nonalcoholic fatty liver NAFLwhich includes steatosis only, and 2 nonalcoholic steatohepatitis NASH characterized by steatosis and inflammation with hepatocyte ballooning, with or without fibrosis, which can progress to liver fibrosis, cirrhosis, hepatocellular carcinoma HCC and liver transplantation 2. Author Biographies C. Hepatology ; 64 1 : Fibrosis progression in nonalcoholic fatty liver disease vs. Clinical gastroenterology and Hepatology ;
Vârsta medie a grupului fără diabet a fost de 70 de ani, iar la cei cu diabet 65,38 de ani, cu o diferență semnificativă statistic. Carcinomul hepatocelular este un cancer frecvent, cu incidență crescută în regiunea noastră, cel mai întâlnit agent cauzal fiind infecția cu virus hepatic B și C.
- Paraziți simptome
Vârsta medie la diagnosticul HCC a fost semnificativ mai mică. Supraviețuirea medie a fost mai mare la pacienții non-diabetici și mortalitatea la un an a fost semnificativ mai mare la pacienții diabetici, relevând că diabetul poate afecta supraviețuirea pe termen lung și că reprezintă un factor de prognostic negativ la acești pacienți.
Throughout the world, there are diagnosed each year approximatelynew cases of HCC. The most common and known risk factor are viral hepatocellular cancer metabolic syndrome, hepatitis virus B or C, toxic factors - alcohol and aflatoxin, immune diseases like primary biliary cirrhosis, plus, in recent years, metabolic risk factors like diabetes and non-alcoholic hepatic steatosis 2,3.
A possible explanation for the hepatocellular cancer metabolic syndrome of diabetes with hepatocellular carcinoma is that diabetes is often part of the metabolic syndrome characterized by clinical and biochemical changes that include alterations in glucose metabolism and insulin, causing hyperglycemia and hyperinsulinemia, dyslipidemia and hypertension.
Metabolic disorders associated with metabolic syndrome can cause diabetes and furthermore contribute to the development of NAFLD non-alchoolic fatty liver disease and its most severe form, non-alcoholic steatohepatitis, so HCC can result from liver cirrhosis caused by NAFLD 4,5,6. Type II diabetes has an increased hepatocellular cancer metabolic syndrome worldwide.
Epidemiologically, the hepatocellular cancer metabolic syndrome between HCV infection and diabetes is known, diabetes being reported to increase the risk of hepatocellular carcinoma in patients with chronic hepatitic C and also contributes to the excess mortality in this patients 7,8. Management of hepatocellular carcinoma is influenced by tumor status, liver function and by comorbidities, and diabetes is one of them 9, Material and methods This is an observational study conducted in the Department of Oncology, Clinical Emergency County Hospital of Constanţa, for a period of four years, from to One hundred and sixty-five patients diagnosed with hepatocellular carcinoma were included in this study.
Impactul diabetului de tip 2 asupra prognosticului pacienților cu carcinom hepatocelular
Patients were divided in two groups regarding the presence or absence of type II diabetes. Demographic profile, clinical features, etiology, tumor size, and presence of portal vein thrombosis were compared between groups.
Data were evaluated using the statistical program SPSS Qualitative data included descriptive statistics, continuous variables are expressed as Mean and Standard Deviation, and T test was used to compare the two groups.